Lates News

According to AI Express, China Post Securities released a research report on September 9 giving Jiangsu Hengrui Medicine Co., Ltd. (600276.SH) a "buy" rating. The reasons for the rating mainly include: 1) The license revenue in the first half of 2025 reached 1.99 billion yuan, with steady growth in innovative drugs; 2) The research and development of oncology and chronic disease immunotherapy are progressing simultaneously, and the employee stock ownership plan clearly outlines the future output plan for innovative drugs. (Daily Economic News)